Details of the Drug Combination

General Information of Drug Combination (ID: DCLWFWN)

Drug Combination Name

Picoplatin Idarubicin

Indication

Disease Entry	Status	REF
Cutaneous melanoma	Investigative	[1]

Component Drugs

Picoplatin DM0PIY6

Idarubicin DMM0XGL

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: SK-MEL-28

Zero Interaction Potency (ZIP) Score: 4.6

Bliss Independence Score: 6.74

Loewe Additivity Score: 2.01

LHighest Single Agent (HSA) Score: 1.67

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Picoplatin

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 3	[2]
Ovarian cancer	2C73	Phase 3	[2]
Prostate cancer	2C82.0	Phase 3	[2]
Small-cell lung cancer	2C25.Y	Phase 3	[2]

Indication(s) of Idarubicin

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Approved	[3]
Acute myeloid leukaemia	2A60	Approved	[4]
Adult acute monocytic leukemia	N.A.	Approved	[3]
Childhood acute megakaryoblastic leukemia	N.A.	Approved	[3]
Leukemia	N.A.	Approved	[3]

Idarubicin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Modulator	[6]
------------------------------------------------------------------------------------

Idarubicin Interacts with 3 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[7]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]
------------------------------------------------------------------------------------

Idarubicin Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[9]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[9]
------------------------------------------------------------------------------------

Idarubicin Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Natriuretic peptides B (NPPB)	OTSN2IPY	ANFB_HUMAN	Increases Expression	[10]
Bile acid receptor (NR1H4)	OTWZLPTB	NR1H4_HUMAN	Decreases Activity	[5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Astrocytoma	DCEKTE2	SNB-19	Investigative	[11]
Glioblastoma	DCXA09B	SNB-75	Investigative	[11]
Glioblastoma?	DCR5PN8	T98G	Investigative	[11]
Glioma	DCX3TV5	SF-295	Investigative	[11]
Renal cell carcinoma	DCXEOXT	SN12C	Investigative	[11]
Adenocarcinoma	DCLC14G	NCIH23	Investigative	[1]
Adenocarcinoma	DCFADXK	HCT-15	Investigative	[1]
Adenocarcinoma	DCRIPRT	HT29	Investigative	[1]
Cutaneous melanoma	DC283XI	SK-MEL-5	Investigative	[1]
Lung adenocarcinoma	DC0CNKO	HOP-62	Investigative	[1]
Melanoma	DC40G82	MALME-3M	Investigative	[1]
Pleural epithelioid mesothelioma	DC0WOVR	NCI-H226	Investigative	[1]
Prostate carcinoma	DCJI9IV	PC-3	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 13 DrugCom(s)

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2	ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3	Idarubicin FDA Label
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
5	Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
8	Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
9	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
10	The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52(5):430-4.
11	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966